Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Paragon Biomedical | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental |
| |
| B | Active Comparator |
| |
| C | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABT-874 | Biological | SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8 |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12 | 12 Weeks | |
| Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12 | 12 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12 | 12 Weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Martin Kaul, MD | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site Reference ID/Investigator# 8478 | Tucson | Arizona | 85710 | United States | ||
| Site Reference ID/Investigator# 8462 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21574983 | Derived | Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011 Sep;165(3):652-60. doi: 10.1111/j.1365-2133.2011.10418.x. Epub 2011 Aug 4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| etanercept |
| Biological |
SQ injection 50 mg BIW |
|
| placebo | Drug | SQ placebo injections for ABT-874 and etanercept |
|
| Fresno |
| California |
| 93720 |
| United States |
| Site Reference ID/Investigator# 8454 | Los Angeles | California | 90045 | United States |
| Site Reference ID/Investigator# 8476 | Denver | Colorado | 80209 | United States |
| Site Reference ID/Investigator# 9641 | Miami | Florida | 33136 | United States |
| Site Reference ID/Investigator# 8463 | Alpharetta | Georgia | 30022 | United States |
| Site Reference ID/Investigator# 8479 | Arlington Heights | Illinois | 60005 | United States |
| Site Reference ID/Investigator# 8527 | Schaumburg | Illinois | 60194 | United States |
| Site Reference ID/Investigator# 9001 | Skokie | Illinois | 60077 | United States |
| Site Reference ID/Investigator# 8466 | West Dundee | Illinois | 60118 | United States |
| Site Reference ID/Investigator# 8467 | Indianapolis | Indiana | 46256 | United States |
| Site Reference ID/Investigator# 8464 | Boston | Massachusetts | 02111 | United States |
| Site Reference ID/Investigator# 8459 | St Louis | Missouri | 63117 | United States |
| Site Reference ID/Investigator# 8473 | East Windsor | New Jersey | 08520 | United States |
| Site Reference ID/Investigator# 8457 | New Brunswick | New Jersey | 08903 | United States |
| Site Reference ID/Investigator# 8447 | Albuquerque | New Mexico | 87106 | United States |
| Site Reference ID/Investigator# 8475 | New York | New York | 10029-6501 | United States |
| Site Reference ID/Investigator# 8468 | Cincinnati | Ohio | 45219 | United States |
| Site Reference ID/Investigator# 8460 | Cleveland | Ohio | 44106 | United States |
| Site Reference ID/Investigator# 9762 | Oklahoma City | Oklahoma | 73104 | United States |
| Site Reference ID/Investigator# 8480 | Lake Oswego | Oregon | 97035 | United States |
| Site Reference ID/Investigator# 8469 | Portland | Oregon | 97210 | United States |
| Site Reference ID/Investigator# 9566 | Portland | Oregon | 97223 | United States |
| Site Reference ID/Investigator# 9761 | Hershey | Pennsylvania | 17033 | United States |
| Site Reference ID/Investigator# 8471 | Philadelphia | Pennsylvania | 19103 | United States |
| Site Reference ID/Investigator# 8449 | Johnston | Rhode Island | 02919 | United States |
| Site Reference ID/Investigator# 8448 | Providence | Rhode Island | 02903 | United States |
| Site Reference ID/Investigator# 8456 | Greer | South Carolina | 29651 | United States |
| Site Reference ID/Investigator# 8458 | Goodlettsville | Tennessee | 37072 | United States |
| Site Reference ID/Investigator# 8461 | Austin | Texas | 78759 | United States |
| Site Reference ID/Investigator# 10542 | Dallas | Texas | 75246-1613 | United States |
| Site Reference ID/Investigator# 8452 | Houston | Texas | 77030 | United States |
| Site Reference ID/Investigator# 8474 | San Antonio | Texas | 78229 | United States |
| Site Reference ID/Investigator# 8482 | Tyler | Texas | 75703 | United States |
| Site Reference ID/Investigator# 8472 | Norfolk | Virginia | 23507 | United States |
| ID | Term |
|---|---|
| C544528 | briakinumab |
| D000068800 | Etanercept |
| ID | Term |
|---|---|
| D007141 | Immunoglobulin Fc Fragments |
| D007128 | Immunoglobulin Fragments |
| D010446 | Peptide Fragments |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D007127 | Immunoglobulin Constant Regions |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D018124 | Receptors, Tumor Necrosis Factor |
| D018121 | Receptors, Cytokine |
| D011971 | Receptors, Immunologic |
| D011956 | Receptors, Cell Surface |
| D008565 | Membrane Proteins |
Not provided
Not provided